跳至主要内容
临床试验/NCT02613325
NCT02613325已完成1 期

Pilot Study to Determine the Feasibility and Functionality of fPAM Imaging for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth

Washington University School of Medicine2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2015年6月8日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
24
试验地点
2
主要终点
In vivo studies using fPAM pigmented lesions imaging to measure tumor depth

研究概览

简要总结

The investigators propose the use of functional photoacoustic microscopy (fPAM) to evaluate both benign and malignant pigmented lesions for tumor depth. Through fPAM analysis followed by histological examination, the investigators anticipate that they will be able to non-invasively determine tumor depth of pigmented lesions (moles and melanoma). In melanoma, tumor depth (Breslow's depth) is not only an important prognostic indicator, but also directs surgical treatment. The ultimate goal is to develop a sensitive clinical tool that will allow non-surgical evaluation of pigmented lesions, which eventually, will aid in melanoma diagnosis and management - potentially an earlier and more definitive surgical management.

In addition, the investigators propose to use the combination of fPAM and single-cell PAM to respectively image CTCs in trunk vessels and cuticle capillaries. Based on the investigators' murine models, the investigators anticipate that they will be able to differentiate CTCs from other blood cells and reliably calculate CTC concentration in a non-invasive manner. CTC concentration has been demonstrated to be a valuable indicator of a melanoma's metastatic potential and a potential tool in evaluating treatment efficacy. The ultimate goal is to develop a sensitive imaging device that will allow accurate evaluation of the risk of melanoma recurrence and metastases, that may facilitate treatment monitoring.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Outcome Measure #1 and #2
  • Healthy individuals with pigmented lesions or a partially biopsied melanoma whose treatment plan includes excision
  • Participants must be 18 years or older
  • Participants must be able to understand and willing to sign a written informed consent document
  • Outcome Measures #3 and #4
  • Patients with either cutaneous, visceral or brain melanoma metastases.
  • Participants must be 18 years or older.
  • Participants must be Eastern Cooperative Oncology Group (ECOG) status 0-
  • Participants must be able to understand and willing to sign a written informed consent document.

排除标准

  • Minors, pregnant patients, incarcerated individuals, and individuals unable to give informed consent will be excluded from this study
  • ECOG status > 3

研究组 & 干预措施

Arm 1: fPAM imaging & Single cell PAM imaging

Experimental
  • fPAM imaging will be performed prior to scheduled excision. The time to excision will not be extended longer than 2 weeks for imaging purposes.
  • When the participant presents for imaging, the area of the thickest lesion depth will be determined by fPAM. The area of deepest thickness will be marked perpendicular to the longest axis of the lesions and a clinical photo will be taken and placed in the image storage database.
  • Surgical excision will be performed as standard of care and fPAM depth will be compared with histological examination.
  • To image CTCs in cutaneous blood vessels, a small cuticle area on a finger will be imaged (Single cell PAM imaging) and the most distal cutaneous metastasis or metastasis of largest diameter will be imaged

干预措施: Single cell photoacoustic microscopy (Device)

Arm 1: fPAM imaging & Single cell PAM imaging

Experimental
  • fPAM imaging will be performed prior to scheduled excision. The time to excision will not be extended longer than 2 weeks for imaging purposes.
  • When the participant presents for imaging, the area of the thickest lesion depth will be determined by fPAM. The area of deepest thickness will be marked perpendicular to the longest axis of the lesions and a clinical photo will be taken and placed in the image storage database.
  • Surgical excision will be performed as standard of care and fPAM depth will be compared with histological examination.
  • To image CTCs in cutaneous blood vessels, a small cuticle area on a finger will be imaged (Single cell PAM imaging) and the most distal cutaneous metastasis or metastasis of largest diameter will be imaged

干预措施: Functional photoacoustic microscopy (Device)

Arm 1: fPAM imaging & Single cell PAM imaging

Experimental
  • fPAM imaging will be performed prior to scheduled excision. The time to excision will not be extended longer than 2 weeks for imaging purposes.
  • When the participant presents for imaging, the area of the thickest lesion depth will be determined by fPAM. The area of deepest thickness will be marked perpendicular to the longest axis of the lesions and a clinical photo will be taken and placed in the image storage database.
  • Surgical excision will be performed as standard of care and fPAM depth will be compared with histological examination.
  • To image CTCs in cutaneous blood vessels, a small cuticle area on a finger will be imaged (Single cell PAM imaging) and the most distal cutaneous metastasis or metastasis of largest diameter will be imaged

干预措施: Standard of care surgical excision (Procedure)

结局指标

主要结局

In vivo studies using fPAM pigmented lesions imaging to measure tumor depth

时间窗: Up to 2 weeks

Validate the lesion depth estimated by fPAM

时间窗: Up to 2 weeks

-The thickness as measured by fPAM will be compared with the thickness of the formalin fixed excised lesion.

次要结局

  • Feasibility and functionality of fPAM as measured by CTC detection(Up to 2 weeks)
  • Feasibility and functionality of single-cell PAM as measured by CTC detection(Up to 2 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验